Granted Patent
B2
US 12,508,212 · App. 18/304,877 · Granted Dec 30, 2025
Phosphate crosslinked starch nanoparticle and dental treatments
Assignee:
GREENMARK BIOMEDICAL INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A phosphorous compound such as STMP is used as a cross-linking agent while making a starch nanoparticle in an emulsion process. Negative charge of the nanoparticle is reduced or reversed by adding cations and/or cationizing the starch optionally while forming the nanoparticles. Anionic active agents, such as fluoride or fluorescein, are optionally incorporated into the nanoparticle during the formation process. For example, a fluoride salt can also be used, which promotes the crosslinking reaction while also providing fluoride in the nanoparticle. The retention of both calcium and fluoride in the nanoparticle is improved when both salts are used. Alternatively, the nanoparticle may be used without added calcium and/or fluoride. The nanoparticles may be useful for tooth remineralization, the treatment of dentinal hypersensitivity, to treat caries, or as a diagnostic agent to locate carious lesions.
Claims (24)
1 . A method of making nanoparticles comprising the steps of,
preparing a first phase comprising a solution or dispersion of starch in water;
preparing a dispersion or emulsion of the first phase in a second liquid phase;
adding one or more of (a) one or more anionic active agents, and (b) one or more multi-valent cations to the first phase; and,
crosslinking the starch in the first phase with a phosphate crosslinker.
2 . The method of claim 1 wherein the second liquid phase is an oil phase.
3 . The method of claim 1 comprising adding an anionic active agent.
4 . The method of claim 3 wherein the anionic active agent comprises fluoride.
5 . The method of claim 3 wherein the anionic active agent is sodium fluoride.
6 . The method of claim 3 wherein the anionic active agent is added to the first phase before preparing an emulsion or dispersion of the first phase in the second liquid phase.
7 . The method of claim 3 wherein the anionic active agent comprises fluorescein.
8 . The method of claim 7 wherein the fluorescein is added as a fluorescein salt.
9 . The method of claim 7 wherein the fluorescein is added as sodium fluorescein.
10 . The method of claim 7 wherein the fluorescein is added to the first phase before preparing the emulsion or dispersion of the first phase in the second liquid phase.
11 . The method of claim 1 comprising adding one or more multivalent cations.
12 . The method of claim 11 wherein the one or more multivalent ions comprises calcium.
13 . The method of claim 11 wherein the one or more multivalent cations are added to the first phase as calcium chloride.
14 . The method of claim 11 wherein the multivalent cations are added to the first phase while or after preparing the emulsion or dispersion of the first phase in the second liquid phase.
15 . The method of claim 11 further comprising adding one or more starch cationizing agents.
16 . The method of claim 1 wherein the one or more multi-valent cations are added in an amount sufficient to produce nanoparticles having a positive zeta potential at a pH of 5.5 or less.
17 . The method of claim 1 wherein the crosslinker comprises sodium trimetaphosphate.
18 . The method of claim 1 comprising mixing the emulsion of the water phase in an oil phase with sufficient shear to produce nanoparticles having an average or mean size in the range of 100-700 nm as determined by the Z-average size in dynamic light scattering (DLS).
19 . The method of claim 1 comprising mixing the emulsion of the water phase in an oil phase with sufficient shear to produce nanoparticles having an average or mean size in the range of 100-500 nm as determined by the Z-average size in dynamic light scattering (DLS).
20 . The method of claim 1 further comprising incorporating the nanoparticles into an aqueous dispersion, a gel or a paste.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 14, 2024
From: BLOEMBERGEN, STEVEN; JONES, NATHAN A.
To: GREENMARK BIOMEDICAL INC.
Reel/Frame 067731/0685 →
Continuity (4)
Division
16966784
Provisional Application
62661669
· Apr 24, 2018
Provisional Application
62648986
· Mar 28, 2018
References Cited (235)
US 675915A
· Woods
· 1901
[cited by applicant]
US 2148951A
· Maxwell
· 1939
[cited by applicant]
US 2328537A
· Felton et al.
· 1943
[cited by applicant]
US 2425058A
· Craig
· 1947
[cited by applicant]
US 2500950A
· Konigsberg
· 1950
[cited by applicant]
US 2801242A
· Kerr et al.
· 1957
[cited by applicant]
US 2819240A
· De Groote et al.
· 1958
[cited by applicant]
US 2824099A
· Craig
· 1958
[cited by applicant]
US 2929811A
· Hofreiter et al.
· 1960
[cited by applicant]
US 2989521A
· Senti et al.
· 1961
[cited by applicant]
US 4126669A
· Rothman et al.
· 1978
[cited by applicant]
US 5049375A
· Tsujita
· 1991
[cited by examiner]
US 5087649A
· Wegner et al.
· 1992
[cited by applicant]
US 6011092A
· Seppaelae et al.
· 2000
[cited by applicant]
US 6340527B1
· Van Soest et al.
· 2002
[cited by applicant]
US 6379494B1
· Jewell et al.
· 2002
[cited by applicant]
US 6677386B1
· Giezen
· 2004
[cited by examiner]
US 6749868B1
· Desai et al.
· 2004
[cited by applicant]
US 6755915B1
· Van Soest et al.
· 2004
[cited by applicant]
US 6825252B2
· Helbling et al.
· 2004
[cited by applicant]
US 6921430B2
· Bloembergen et al.
· 2005
[cited by applicant]
US 7550441B2
· Farokhzad et al.
· 2009
[cited by applicant]
US 8043480B2
· Lahann et al.
· 2011
[cited by applicant]
US 8048453B1
· Sung et al.
· 2011
[cited by applicant]
US 8759322B2
· Akiyoshi et al.
· 2014
[cited by applicant]
US 9133279B2
· Perrier et al.
· 2015
[cited by applicant]
US 20020136769A1
· Kabanov et al.
· 2002
[cited by applicant]
US 20030219785A1
· Hallahan et al.
· 2003
[cited by applicant]
US 20040039042A1
· Fleming
· 2004
[cited by applicant]
US 20040126900A1
· Barry et al.
· 2004
[cited by applicant]
US 20040241382A1
· Bloembergen et al.
· 2004
[cited by applicant]
US 20050191359A1
· Goldshtein et al.
· 2005
[cited by applicant]
US 20080241257A1
· Popescu et al.
· 2008
[cited by applicant]
US 20090117549A1
· Tan et al.
· 2009
[cited by applicant]
US 20090312402A1
· Contag et al.
· 2009
[cited by applicant]
US 20100093659A1
· Natunen et al.
· 2010
[cited by applicant]
US 20100143738A1
· Bloembergen et al.
· 2010
[cited by applicant]
US 20100166872A1
· Singh et al.
· 2010
[cited by applicant]
US 20100267802A1
· Sullenger
· 2010
[cited by applicant]
US 20100272639A1
· Dutcher
· 2010
[cited by applicant]
US 20110014296A1
· Chen et al.
· 2011
[cited by applicant]
US 20110038939A1
· Lvov et al.
· 2011
[cited by applicant]
US 20110244044A1
· Rossi et al.
· 2011
[cited by applicant]
US 20120003888A1
· Lee et al.
· 2012
[cited by applicant]
US 20120141551A1
· Bloembergen et al.
· 2012
[cited by applicant]
US 20150299431A1
· Parcq et al.
· 2015
[cited by applicant]
EP 0311873A2
· 1989
[cited by applicant]
EP 1159301B1
· 2003
[cited by applicant]
EP 1961769A1
· 2008
[cited by applicant]
EP 1303670B1
· 2010
[cited by applicant]
EP 1303667B1
· 2010
[cited by applicant]
EP 2251484B1
· 2017
[cited by applicant]
GB 1420392A
· 1976
[cited by applicant]
JP 2002544335A
· 2002
[cited by applicant]
JP 2004500438A
· 2004
[cited by applicant]
JP 2005535604A
· 2005
[cited by applicant]
WO 0040617A1
· 2000
[cited by applicant]
WO 0066090A1
· 2000
[cited by applicant]
WO 0069916A1
· 2000
[cited by applicant]
WO 0178786A2
· 2001
[cited by applicant]
WO 03010206A1
· 2003
[cited by applicant]
WO 03101425A2
· 2003
[cited by applicant]
WO 2005108471A1
· 2005
[cited by applicant]
WO 2007069272A2
· 2007
[cited by applicant]
WO 2008022127A2
· 2008
[cited by applicant]
WO 2008060575A2
· 2008
[cited by applicant]
WO 2009146147A2
· 2009
[cited by applicant]
WO 2010042823A1
· 2010
[cited by applicant]
WO 2010053140A1
· 2010
[cited by applicant]
WO 2010065750A1
· 2010
[cited by applicant]
WO 2010080557A1
· 2010
[cited by applicant]
WO 2010084060A1
· 2010
[cited by applicant]
WO 2010084088A2
· 2010
[cited by applicant]
WO 2011071742A2
· 2011
[cited by applicant]
WO 2011155979A2
· 2011
[cited by applicant]
WO 2012075414A2
· 2012
[cited by applicant]
WO 2012162845A1
· 2012
[cited by applicant]
WO 2013081720A1
· 2013
[cited by applicant]
WO 2017070578A1
· 2017
[cited by applicant]
WO WO2017070578
· 2017
[cited by examiner]
Jones et al., “Nanoparticle-Based Targeting and Detection of Microcavities.” Advanced Healthcare Materials 2017, issue 6, 1600883 (9 pages). Published online: Nov. 15, 2016. (Year: 2016).
[cited by examiner]
Dziecheiarek et al., “Preparation and Properties of Starch-Based Colloidal Microgels.” Journal of Colloid and Interface Science 246, 48-59 (2002). (Year: 2002).
[cited by examiner]
Alexiou et al., “Targeting Cancer Cells: Magnetic Nanoparticles as Drug Carriers,” European Biophysics Journal, 2006, vol. 35(5), pp. 446-450.
[cited by applicant]
Alonso et al., “Antimetastatic Effect of Desmopressin in a Mouse Mammary Tumor Model,” Breast Cancer Research and Treatment, Oct. 1999, vol. 57 (3), pp. 271-275.
[cited by applicant]
Alzate P., et al., “Micro and Nanoparticles of Native and Modified Cassava Starches as Carriers of the Antimicrobial Potassium Sorbate,” Starch, 2016, vol. 68(11-12), pp. 1038-1047.
[cited by applicant]
Amin et al., “Hydrogels as Potential Drug Delivery Systems,” Scientific Research and Essay, Dec. 2009, vol. 3 (11), pp. 1175-1183.
[cited by applicant]
Anonymous, “The Influence of Zeta Potential” , silvercolloids.com, Mar. 9, 2018, 1 page.
[cited by applicant]
Aravind et al., “Aptamer-Labeled PLGA Nanoparticles for Targeting Cancer Cells,” Cancer Nano, 2012, vol. 3(1-6), pp. 1-12.
[cited by applicant]
Barker et al., “The Synthesis and Characterization of a Novel Polysaccharide Hydrogel for Biomedical Applications Including the Treatment of Malignant Tumors and the Prevention of Metastatic Disease.” Thesis, University…
[cited by applicant]
Bates et al., “Discovery and Development of the G-Rich Oligonucleotide AS1411 as a Novel Treatment for Cancer,” Experimental and Molecular Pathology, Jun. 2009, vol. 86 (3), pp. 151-164.
[cited by applicant]
Behnan, et al. “In-vitro evaluation of various treatments to prevent demineralization next to orthodontic brackets” , American Journal of Orthodontics and Dentofacial Orthopedics, Dec. 2010, pp. 712.e1-712.e7.
[cited by applicant]
Blank et al., “Systematic Evolution of a DNA Aptamer Binding to Rat Brain Tumor Microvessels,” Journal of Biological Chemistry, May 2001, vol. 276 (19), pp. 16464-16468.
[cited by applicant]
Bloembergen et al., “Biolatex Binders for Paper and Paperboard Applications,” Journal of Pulp and Paper Science, Jan. 2010, vol. 36 (3), pp. 1-11.
[cited by applicant]
Bloembergen et al., “Paper Binder Performance With Nanoparticle Biolatextm: Ecosynthetix Develops Ecosphere Biolatex for Replacement of Petroleum Based Latex Binders,” ACFS, Montreal, Jun. 11-13, 2008.
[cited by applicant]
Bloembergen, et al., “Specialty Biobased Monomers and Emulsion Polymers Derived from Starch,” Presented to the PTS Advanced Coating Fundamentals Symposium, Munich, Germany, Oct. 11-14, 2010, pp. 1-19.
[cited by applicant]
Bowen, et al., “The Stephan Curve Revisited,” Odontology, 2012, vol. 101, pp. 2-8.
[cited by applicant]
Canadian Patent Application No. 2,790,763, Office Action dated Apr. 30, 2020.
[cited by applicant]
Canadian Patent Application No. 2,790,763, Office Action dated Aug. 6, 2019.
[cited by applicant]
Canadian Patent Application No. 2,790,763, Office Action dated Feb. 21, 2022.
[cited by applicant]
Canadian Patent Application No. 2,790,763, Office Action dated Jan. 12, 2021.
[cited by applicant]
Canadian Patent Application No. 2,790,763, Office Action dated Jul. 23, 2021.
[cited by applicant]
Canadian Patent Application No. 2,790,763, Office Action dated Sep. 25, 2018.
[cited by applicant]
Canadian Patent Application No. 2,819,240, Office Action dated Aug. 28, 2019.
[cited by applicant]
Canadian Patent Application No. 2,819,240, Office Action dated May 8, 2020.
[cited by applicant]
Canadian Patent Application No. 2,819,240, Office Action dated Sep. 26, 2018.
[cited by applicant]
Chinese Patent Application No. 201980022325.0, Office Action dated May 25, 2022.
[cited by applicant]
Corre et al., “Starch Nanoparticles: A Review,” Biomacromolecules, May 2010, vol. 11 (5), pp. 1139-1153.
[cited by applicant]
Dave et al., “Regenerable DNA-Functionalized Hydrogels for Ultrasensitive, Instrument-Free Mercury(II) Detection and Removal in Water,” Journal of the American Chemical Society, Aug. 2010, vol. 132 (36), pp. 12668-12673.
[cited by applicant]
Davis, “Microspheres and Drug Therapy: Pharmaceutical, Immunological and Medical Aspects”, Elsevier, New York, NY, USA, Chapter 2, 1984, pp. 25-37.
[cited by applicant]
El-Feky et al., “Utilization of Crosslinked Starch Nanoparticles as a Carrier for Indomethacin and Acyclovir Drugs,” Journal of Nanomedicine & Nanotechnology, 2015, vol. 6(1); 1000254, pp. 1-8.
[cited by applicant]
European Patent Application 11845209, Extended European Search Report dated Mar. 7, 2017.
[cited by applicant]
European U.S. Appl. No. 11/845,209, Supplementary Partial European Search Report dated Jul. 29, 2016.
[cited by applicant]
European Patent Application No. 11845209.3, Office Action dated Nov. 21, 2017.
[cited by applicant]
European Patent Application No. 11845209.3, Office Action dated Oct. 24, 2018.
[cited by applicant]
European Patent Application No. 19774807.2, Extended European Search Report dated Oct. 28, 2021.
[cited by applicant]
Ex Parte Podack Patent Trial and Appeal Board Appeal No. 2014-006893, Nov. 14, 2016, pp. 1-14 and a title page (15 total sheets).
[cited by applicant]
Farokhzad et al., “Nanoparticle-Aptamer Bioconjugates for Cancer Targeting,” Expert Opinion on Drug Delivery, May 2006, vol. 3 (3), pp. 311-324.
[cited by applicant]
Farokhzad et al., “Nanoparticle-Aptamer Bioconjugates: A New Approach for Targeting Prostate Cancer Cells,” Cancer Research, Nov. 2004, vol. 64 (21), pp. 7668-7672.
[cited by applicant]
Fishman et al., “Molar Masses and Sizes of Starches by High-Performance Size-Exclusion Chromatography With On-line Multi-Angle Laser Light Scattering Detection,” Journal of Agricultural and Food Chemistry, Oct. 1996, vo…
[cited by applicant]
Gu et al., “Targeted Nanoparticles for Cancer Therapy,” Nano Today, Jun. 2007, vol. 2 (3), pp. 14-21.
[cited by applicant]
Hamidi et al., “Hydrogel Nanoparticles in Drug Delivery,” Advanced Drug Delivery Reviews, Dec. 2008, vol. 60 (15), pp. 1638-1649.
[cited by applicant]
Heidel et al., “Cyclodextrin-Containing Polymers: Versatile Platforms of Drug Delivery Materials,” Journal of Drug Delivery, 2012, vol. 2012, p. 17.
[cited by applicant]
Herr et al., “Aptamer-Conjugated Nanoparticles for Selective Collection and Detection of Cancer Cells,” Analytical Chemistry, May 2006, vol. 78 (9), pp. 2918-2924.
[cited by applicant]
International Patent Application No. PCT/US2011/063102, International Preliminary Report on Patentability dated Jun. 13, 2013.
[cited by applicant]
International Patent Application No. PCT/US2011/063102, International Search Report and Written Opinion dated Jul. 6, 2012.
[cited by applicant]
International Patent Application No. PCT/US2012/056582, International Preliminary Report on Patentability dated Jun. 12, 2014.
[cited by applicant]
International Patent Application No. PCT/US2012/056582, International Search Report and Written Opinion dated Feb. 28, 2013.
[cited by applicant]
International Patent Application No. PCT/US2019/024619, International Preliminary Report on Patentability dated Sep. 29, 2020.
[cited by applicant]
International Patent Application No. PCT/US2019/024619, International Search Report dated Jun. 27, 2019.
[cited by applicant]
Jain et al., “Effective Insulin Delivery Using Starch Nanoparticles as a Potential Trans-Nasal-Nucoadhesive Carrier,” European Journal of Pharmaceutics, Jun. 2008, vol. 69 (2), pp. 426-435.
[cited by applicant]
Canadian Patent Application No. 3,090,303, Office Action dated Dec. 21, 2023.
[cited by applicant]
U.S. Appl. No. 13/614, 120, Office Action dated Jul. 24, 2014.
[cited by applicant]
U.S. Appl. No. 13/614, 120, Office Action dated Jul. 29, 2013.
[cited by applicant]
U.S. Appl. No. 13/614, 120, Office Action dated Jun. 13, 2014.
[cited by applicant]
U.S. Appl. No. 13/990,278, Final Office Action dated Jan. 22, 2018.
[cited by applicant]
U.S. Appl. No. 13/990,278, Non-Final Office Action dated Jul. 23, 2018.
[cited by applicant]
U.S. Appl. No. 13/990,278, Non-Final Office Action dated Jun. 14, 2017.
[cited by applicant]
U.S. Appl. No. 13/990,278, Non-Final Office Action dated Nov. 23, 2016.
[cited by applicant]
U.S. Appl. No. 13/990,278, Non-Final Office Action dated Sep. 13, 2018.
[cited by applicant]
U.S. Appl. No. 13/990,278, Notice of Allowance dated Jan. 15, 2019.
[cited by applicant]
U.S. Appl. No. 13/990,278, Notice of Allowance dated Mar. 30, 2018.
[cited by applicant]
U.S. Appl. No. 13/990,278, Office Action dated Aug. 3, 2015.
[cited by applicant]
U.S. Appl. No. 13/990,278, Office Action dated Mar. 20, 2014.
[cited by applicant]
U.S. Appl. No. 13/990,278, Office Action dated May 5, 2016.
[cited by applicant]
U.S. Appl. No. 13/990,278, Office Action dated Oct. 9, 2015.
[cited by applicant]
U.S. Appl. No. 14/360,503 Notice of Allowance dated Feb. 25, 2022.
[cited by applicant]
U.S. Appl. No. 14/360,503, Final Office Action dated Aug. 16, 2018.
[cited by applicant]
U.S. Appl. No. 14/360,503, Final Office Action dated Sep. 9, 2016.
[cited by applicant]
U.S. Appl. No. 14/360,503, Non-Final Office Action dated Jan. 22, 2016.
[cited by applicant]
U.S. Appl. No. 14/360,503, Non-Final Office Action dated Nov. 24, 2017.
[cited by applicant]
U.S. Appl. No. 14/360,503, Notice of Allowance dated Apr. 4, 2022.
[cited by applicant]
U.S. Appl. No. 14/360,503, Notice of Allowance dated Nov. 9, 2021.
[cited by applicant]
U.S. Appl. No. 14/360,503, Office Action dated Aug. 10, 2015.
[cited by applicant]
U.S. Appl. No. 16/383,998, Final Office Action dated Mar. 24, 2020.
[cited by applicant]
U.S. Appl. No. 16/383,998, Final Office Action dated Nov. 10, 2020.
[cited by applicant]
U.S. Appl. No. 16/383,998, Non-Final Office Action dated Apr. 16, 2021.
[cited by applicant]
U.S. Appl. No. 16/383,998, Non-Final Office Action dated Jul. 2, 2020.
[cited by applicant]
U.S. Appl. No. 16/383,998, Non-Final Office Action dated Oct. 25, 2021.
[cited by applicant]
U.S. Appl. No. 16/391,918, Final Office Action dated Jun. 29, 2021.
[cited by applicant]
U.S. Appl. No. 16/391,918, Non-Final Office Action dated Sep. 4, 2020.
[cited by applicant]
Wang et al., “Superparamagnetic Iron Oxide Nanoparticle-Aptamer Bioconjugates for Combined Prostate Cancer Imaging andTherapy.” ChemMedChem, vol. 3, 2008, pp. 1311-1315.
[cited by applicant]
Wenz, “Cyclodextrine als Bausteine supramolekularer Strukturen and Funktionseinten,” Angewandte Chemie, 1994, vol. 106, pp. 851-870.
[cited by applicant]
Wu et al., “DNA Aptamer-Micelle as an Efficient Detection/Delivery Vehicle Toward Cancer Cells,” Proceedings of the National Academy of Sciences of the United States of America, Jan. 2010, vol. 107 (1), pp. 5-10.
[cited by applicant]
Xiao et al., “Preparation of Folate-Conjugated Starch Nanoparticles and its Application to Tumor-Targeted Drug Delivery Vector,” Chinese Science Bulletin, Jul. 2006, vol. 51 (14), pp. 1693-1697.
[cited by applicant]
Xiao et al., “Studies of Poly-L-Lysine-Starch Nanoparticle Preparation and its Application as Gene Carrier,” Science in China Series B Chemistry, Mar. 2005, vol. 48 (2), pp. 162-166.
[cited by applicant]
Yamada et al., “Design of Folate-Linked Liposomal Doxorubicin to Its Antitumor Effect in Mice,” Clinical Cancer Research, Dec. 2008, vol. 14 (24), pp. 8161-8168.
[cited by applicant]
Yang et al., “Investigation of Folate-Conjugated Fluorescent Silica Nanoparticles for Targeting Delivery to Folate Receptor-Positive Tumors and Their Internalization Mechanism,” International Journal of Nanomedicine, 20…
[cited by applicant]
U.S. Appl. No. 16/966,784, Office Action dated Sep. 29, 2022.
[cited by applicant]
U.S. Appl. No. 16/966,784, Notice of Allowance dated Jan. 23, 2023.
[cited by applicant]
Japanese Patent Application No. 2020-551969, Office Action dated May 9, 2023.
[cited by applicant]
Japanese Patent Application No. 2020-551969, Office Action dated Feb. 13, 2024.
[cited by applicant]
U.S. Appl. No. 17/376,837, Office Action dated Jul. 10, 2023.
[cited by applicant]
U.S. Appl. No. 17/376,837, Office Action dated Sep. 19, 2023.
[cited by applicant]
Jones et al., “Nanoparticle-Based Targeting and Detection of Microcavities” , Advanced Healthcare Materials, vol. 6, Article No. 1600883, Nov. 15, 2016, p. 1-9.
[cited by applicant]
Jones, et al., “Targeted Starch Nanoparticles for Cancer Therapy”, Design Symposium, Mar. 23, 2012.
[cited by applicant]
Kaptein S.J.F., et al., “A Derivate of the Antibiotic Doxorubicin is a Selective Inhibitor of Dengue and Yellow Fever Virus Replication in Vitro,” Antimicrobial Agents and Chemotherapy, 2010, vol. 54(12), pp. 5269-5280.
[cited by applicant]
Kawano et al., “Effects of Polyethylene Glycol Spacer Length and Ligand Density on Folate Receptor Targeting of Liposomal Doxorubicin in Vitro,” Journal of Drug Delivery, 2011, vol. 2011, Article ID 160967, 6 pages.
[cited by applicant]
Khiavi et al., “Therapeutic Efficacy of Orally Delivered Doxorubicin Nanoparticles in Rat Tongue Cancer Induced by 4-Nitroquinoline 1-Oxide,” Advanced Pharmaceutical Bulletin, Jun. 2015, vol. 5 (2), pp. 209-216.
[cited by applicant]
Lai, et al., “AS1411 Aptamer-Conjugated Polymeric Micelle for Targetable Cancer Therapy,” Nanotech Conference and Expo 2010, Anaheim, CA, Abstract, Jun. 21-24, 2010.
[cited by applicant]
Lee et al., “Delivery of Liposomes Into Cultured KB Cells via Folate Receptor-Mediated Endocytosis,” The Journal of Biological Chemistry, Feb. 1994, vol. 269 (5), pp. 3198-3204.
[cited by applicant]
Lee et al., “Development of New Biobased Emulsion Binders,” Presented at Papercon 2010, Talent, Technology And Transformation, Altanta, GA, May 2-5, 2010.
[cited by applicant]
Li, Bing-Zheng et al. “Fabrication of starch-based microparticles by an emulsification-crosslinking method” , Journal of Food Engineering 92 (2009) 250-254.
[cited by applicant]
Li, Bing-Zheng et al. “Physical properties and loading capacity of starch-based microparticles crosslinked with trisodium trimetaphosphate” , Journal of Food Engineering 92 (2009) 255-260.
[cited by applicant]
Ma et al., “Fabrication and Characterization of Citric Acid-modified Starch Nanoparticles/Plasticized-starch 2, Omposites,” Biomacromolecules, 2008, vol. 9, pp. 3314-3320.
[cited by applicant]
Mangalam et al., “Cellulose/DNA Hybrid Nanomaterials,” Biomacromolecules, Mar. 2009, vol. 10 (3), pp. 497-504.
[cited by applicant]
Milla et al., “PEGylation of Proteins and Liposomes: A Powerful and Flexible Strategy to Improve the Drug Delivery,” Current Drug Metabolism, Jan. 2012, vol. 13 (1), pp. 105-119.
[cited by applicant]
Mongelard et al., “AS-1411, A Guanosine-Rich Oligonucleotide Aptamer Targeting Nucleolin for the Potential Treatment of Cancer, Including Acute Myeloid Leukemia,” Current Opinion in Molecular Therapeutics, Feb. 2010, vo…
[cited by applicant]
Moore M.D., et al., “Generation of neutralizing aptamers against herpes simplex virus type 2: potential components of multivalent microbicides,” The Journal of general virology, 2011, pp. 1493-1499.
[cited by applicant]
Nationwide Children's Hospital, Herpes Simplex Virus (HSV), Jun. 1993. pp. 1-2.
[cited by applicant]
Ozalp et al., “Aptamer-Gated Nanoparticles for Smart Drug Delivery,” Pharmaceuticals, 2011, vol. 4 (8), pp. 1137-1157.
[cited by applicant]
Peng et al., “Targeted Magnetic Iron Oxide Nanoparticles for Tumor Imaging and Therapy,” International Journal of Nanomedicine, 2008, vol. 3 (3), pp. 311-321.
[cited by applicant]
Phillips et al., “Applications of Aptamers in Cancer Cell Biology,” Analytica Chimica Acta, Jul. 2008, vol. 621 (2), pp. 101-108.
[cited by applicant]
Mukerjea et al., “Determination of the maximum water solubility of eight native starches andthe solubility of their acidic-methanol and -ethanol modified analogues.” Carbohydrate Research, vol. 342 (2007) pp. 1 03-110. …
[cited by applicant]
Saboktakin et al., “pH-sensitive Starch Hydrogels via Free Radical Graft Copolymerization, Synthesis and Properties,” Carbohydrate Polymers, Jul. 2009, vol. 77 (3), pp. 634-638.
[cited by applicant]
Saenger, “Cyclodextrin-Einschubverbindungen in Forschung Ung Industrie,” Angewandte Chemie, 1980, vol. 92, pp. 343-361.
[cited by applicant]
Sasaki et al., “A Combination of Desmopressin and Docetaxel Inhibit Cell Proliferation and Invasion Mediated by Irokinase-type Plasminogen Activator (uPA) in Human Prostate Cancer Cells,” Biochemical and Biophysical Res…
[cited by applicant]
Shangguan et al., “Aptamers Evolved from Cultured Cancer Cells Reveal Molecular Differences of Cancer Cells in Patient Samples,” Clinical Chemistry, Jun. 2007, vol. 53 (6), pp. 1153-1155.
[cited by applicant]
Shangguan et al., “Aptamers evolved from live cells as effective molecular probes for cancer study”, Proceedings of the National Academy of Sciences, Aug. 2006, vol. 103(32), pp. 11838-11843.
[cited by applicant]
Shi et al., “Preparation of Starch-based Nanoparticles Through High-pressure Homogenization and Miniemulsion Cross-linking: Influence of Various Process Parameters on Particle Size and Stability,” Carbohydrate Polymers,…
[cited by applicant]
Shin et al., “Rheological Properties of Starch Latex Dispersions and Starch Latex-containing Coating Colors, Presented at PaperCon 2012, Growing the Future” , New Orleans, LA, Apr. 21-25, 2012, pp. 1-26.
[cited by applicant]
Simi et al., “Hydrophobic Grafted and Cross-linked Starch Nanoparticles for Drug Delivery,” Bioprocess and Biosystems Engineering, May 2007, vol. 30 (3), pp. 173-180.
[cited by applicant]
Simmons et al., “Anti-Heparanase Aptamers as Potential Diagnostic and Therapeutic Agents for Oral Cancer,” PLoS One, 2014, vol. 9 (10), e96846.
[cited by applicant]
Song et al., “Starch Nanoparticle Formation via Reactive Extrusion and Related Mechanism Study,” Carbohydrate Polymers, Apr. 2011, vol. 85 (15), pp. 208-214.
[cited by applicant]
Soontornworajit et al., “Aptamer-Functionalized in Situ Injectable Hydrogel for Controlled Protein Release,” Journal of Biomacromolecules, Sep. 1, 2010, vol. 11 (10), pp. 2724-2730.
[cited by applicant]
Soundararajan et al., “Plasma Membrane Nucleolin is a Receptor for an Anticancer Aptamer AS1411 in MV4-11 Leukemia Cells,” Molecular Pharmacology, Nov. 2009, vol. 76 (5), pp. 984-991.
[cited by applicant]
Stuart et al., “Randomized Phase II Trial of the Nucleolin Targeting Aptamer AS1411 Combined with High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia (AML),” Journal of Clinical Oncology, 2009, vol. 27 (1…
[cited by applicant]
Suk et al., “PEGylation as a Strategy for Improving Nanoparticle-Based Drug and Gene Delivery,” Advanced Drug Delivery Reviews, Apr. 2016, vol. 99 (Pt A), pp. 28-51.
[cited by applicant]
Thapa et al., “Folate-PEG Conjugates of a Far-Red Light-Activatable Paclitaxel Prodrug to Improve Selectivity Toward Folate Receptor-Positive Cancer Cells” ACS Omega, Oct. 2017, vol. 2(10), pp. 6349-6360.
[cited by applicant]
Thiele et al., “Nanoparticle of Anionic Starch and Cationic Cyclodextrin Derivatives for the Targeted Delivery of Drugs,” Polymer Chemistry, Oct. 2010, vol. 2 (1), pp. 209-215.
[cited by applicant]
U.S. Appl. No. 13/614, 120, Office Action dated Feb. 7, 2013.
[cited by applicant]
U.S. Appl. No. 13/310,287, Office Action dated Apr. 3, 2014.
[cited by applicant]
U.S. Appl. No. 13/310,287, Office Action dated Jul. 18, 2013.
[cited by applicant]
U.S. Appl. No. 13/310,287, Office Action dated Jul. 21, 2014.
[cited by applicant]
U.S. Appl. No. 13/310,287, Office Action dated Jul. 5, 2012.
[cited by applicant]
U.S. Appl. No. 13/310,287, Office Action dated Jun. 16, 2014.
[cited by applicant]
U.S. Appl. No. 13/310,287, Office Action dated Nov. 21, 2012.
[cited by applicant]
U.S. Appl. No. 13/310,287, Office Action dated Oct. 31, 2013.
[cited by applicant]
U.S. Appl. No. 13/614, 120, Office Action dated Apr. 4, 2014.
[cited by applicant]
U.S. Appl. No. 13/614, 120, Office Action dated Dec. 8, 2014.
[cited by applicant]